NetworkNewsBreaks – BriaCell Therapeutics Corp.
Post# of 69
(Total Views: 143)
Posted On: 10/18/2018 4:44:40 PM
NetworkNewsBreaks – BriaCell Therapeutics Corp. (TSX.V: BCT) (OTCQB: BCTXF) Lead Clinical Candidate Development Advances Following Promising Phase IIa Results
Clinical-stage biotechnology company BriaCell Therapeutics (TSX.V: BCT) (OTCQB: BCTXF) has achieved proof of concept and recently reported promising results from its Phase IIa study of its lead clinical candidate, Bria-IMT. An article further discussing the company reads, “A total of 31 patients with advanced stage breast cancer were enrolled in the Phase II Bria-IMT monotherapy study. The proof of concept and mechanism of action work is based on the results observed in the first 20 patients, while assessment of the remaining 11 patients is still in progress. …The preliminary data seems to confirm the company’s HLA Matching Hypothesis and support its strategy for the development of Bria-OTS, the first off-the-shelf personalized immunotherapy for advanced breast cancer, designed to provide treatment without the high costs and difficult manufacturing generally associated with personalized therapies. The technology is applicable to other types of cancer, as well.” A combination study with immune checkpoint inhibitors is in the works and enrollment is already open.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Clinical-stage biotechnology company BriaCell Therapeutics (TSX.V: BCT) (OTCQB: BCTXF) has achieved proof of concept and recently reported promising results from its Phase IIa study of its lead clinical candidate, Bria-IMT. An article further discussing the company reads, “A total of 31 patients with advanced stage breast cancer were enrolled in the Phase II Bria-IMT monotherapy study. The proof of concept and mechanism of action work is based on the results observed in the first 20 patients, while assessment of the remaining 11 patients is still in progress. …The preliminary data seems to confirm the company’s HLA Matching Hypothesis and support its strategy for the development of Bria-OTS, the first off-the-shelf personalized immunotherapy for advanced breast cancer, designed to provide treatment without the high costs and difficult manufacturing generally associated with personalized therapies. The technology is applicable to other types of cancer, as well.” A combination study with immune checkpoint inhibitors is in the works and enrollment is already open.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)